Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Raise the Risk of Gallbladder Problems?

Randomized trials found about two extra gallstone cases per 1,000 people. A diabetes cohort also tracked gallbladder inflammation and surgery.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Adjusted odds against matched controlsat 2 yearsat 3 yearsgallbladder or bile duct stones1.441.43cholecystitisnot significant1.45gallbladder removalnot significant1.54pancreatitisnot significantnot significant39,140 people in each matched group

GLP-1 drugs can increase the risk of gallstones. The analysis of gallstones and reflux in 55 randomized trials estimated a gallstone risk ratio of 1.46 (95% CI 1.09–1.97), or about two extra cases per 1,000 people compared with placebo.[2]

What the diabetes cohort found

Researchers matched 39,140 GLP-1 users with 39,140 controls, all adults with type 2 diabetes. At two years, stones in the gallbladder or bile duct were recorded in 440 users (1.13%) and 307 controls (0.79%). The adjusted odds ratio was 1.44 (95% CI 1.24–1.65). At three years it was 1.43 (95% CI 1.24–1.63). Gallbladder inflammation also had higher adjusted odds at three years (1.45, 95% CI 1.14–1.83).[1]

Participants taking GLP-1 drugs had more abdominal imaging, which may have led to more diagnoses of otherwise unnoticed stones. The groups also differed in baseline BMI despite matching. The randomized trials and the cohort both found an increase in stone diagnoses, each with its own population and measure.[1][2]

What the study found about surgery

At two years, gallbladder removal had an adjusted odds ratio of 1.13 (95% CI 0.84–1.54). At three years, 134 GLP-1 users and 87 controls had undergone removal (adjusted odds ratio 1.54, 95% CI 1.17–2.02). Those assessments show when the difference was detectable in this study. They cannot establish when a medication-related risk begins.[1]

Acute pancreatitis and endoscopic bile-duct procedures showed no statistically significant difference at either assessment. Research on GLP-1 use after an episode of pancreatitis addresses a separate question about recurrence. Comparisons by drug in the gallbladder cohort also cannot establish which medication is safest.[1]

Frequently asked

How much does gallstone risk rise on a GLP-1?
A review of 55 randomized trials estimated about two additional gallstone cases per 1,000 people compared with placebo. The estimate reflects the participants and follow-up periods in those trials.
Did GLP-1 users have more gallbladder surgery?
In one matched study of adults with type 2 diabetes, 134 GLP-1 users and 87 controls in groups of 39,140 had gallbladder removal by three years. The difference at two years was statistically uncertain.

Sources

  1. [1] Eldesouki MH, et al. (2026). Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes United European Gastroenterology Journal. PMID 42247589
  2. [2] Chiang CH, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis Gastroenterology. PMID 40499738
  3. [3] Eli Lilly and Company (2026). Zepbound prescribing information, section 5.4 DailyMed. Source
  4. [4] National Institute of Diabetes and Digestive and Kidney Diseases (2017). Symptoms & Causes of Gallstones NIDDK. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence